Article

Atopic dermatitis may precede the onset of delinquent behaviors in children and adolescents


 

Key clinical point: Onset and persistence of atopic dermatitis (AD) in children is associated with delinquent behaviors during childhood and adolescence.

Major finding: AD in children aged 5 years (adjusted odds ratio [aOR] 1.31; 95% CI 1.04-1.64) or 9 years (aOR 1.38; 95% CI 1.14-1.67) was associated with ≥75th percentile of mean delinquent behavior scores at age 9 or 15 years. At 9 years of age, a 1-year history of AD was associated with smoking at age 15 years (aOR 1.46; 95% CI 1.00-2.13), damaging property (aOR 1.38; 95% CI 1.08-1.77), cheating on a test (aOR 1.62; 95% CI 1.17-2.26), and school suspension (aOR 1.36; 95% CI 1.08-1.71).

Study details: Findings are from the prospective, longitudinal birth cohort Fragile Families and Child Wellbeing Study including 4,898 children aged 1, 3, 5, 9, or 15 years, of which 16.4%, 17.5%, and 16% of children aged 5, 9, and 15 years, respectively, had AD.

Disclosures: This study did not report any source of funding. The authors declared no conflicts of interest.

Source: Manjunath J et al. Arch Dermatol Res. 2022 (Jan 10). Doi: 10.1007/s00403-021-02314-y.

Recommended Reading

Sorting out sleep complaints in children with AD can be complex
MDedge Dermatology
Hand eczema and atopic dermatitis closely linked
MDedge Dermatology
Atopic Dermatitis: A supplement to Dermatology News
MDedge Dermatology
FDA approves two JAK-1 inhibitors for moderate to severe atopic dermatitis
MDedge Dermatology
Atopic dermatitis: Rapid and sustained disease control with dupilumab
MDedge Dermatology
Atopic dermatitis not associated with low bone mineral density in young adults
MDedge Dermatology
GlcChol levels and GBA activity could serve as biomarkers of therapeutic response in atopic dermatitis
MDedge Dermatology
Upadacitinib and topical corticosteroids combo safe in mild-to-moderate atopic dermatitis
MDedge Dermatology
Atopic dermatitis: Patients showing suboptimal response to initial dupilumab may benefit from long-term treatment
MDedge Dermatology
Patients with atopic dermatitis at higher risk for COVID-19 infection
MDedge Dermatology